Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Basimglurant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 known ✓ | P41594 | 15/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.73 |
| ▸ | TSPO | P30536 | 1/20 | 0.73 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.73 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.73 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Basimglurant SCHEMBL29377966 | 1.00 | GRM5 (1.00) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL608527 | 0.91 | GRM5 (0.83) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL607411 | 0.90 | GRM5 (0.82) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL607722 | 0.90 | GRM5 (0.82) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL4629677 | 0.88 | GRM5 (0.78) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL609394 | 0.87 | GRM5 (0.78) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL607850 | 0.87 | GRM5 (0.78) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL609263 | 0.87 | GRM5 (0.78) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL608562 | 0.87 | GRM5 (0.78) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL607932 | 0.87 | GRM5 (0.78) | GRM5KCNH2ADRB3TSPOTMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | ORPHELION AB (SE) | 2026-05-07 | — | — | US | claimed |
| US-12605367-B2 | Methods of treatment and/or prevention of disorders and symptoms related to BKCa and/or SK channelophathies | Universite de Bordeaux (FR) | 2026-04-21 | — | — | US | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| US-20250360118-A1 | TREATMENT OF FIBROTIC DISORDERS WITH METABOTROPIC GLUTAMATE RECEPTOR 5 ANTAGONISTS OR/AND CANNABINOID RECEPTOR 1 ANTAGONISTS | US HEALTH (US) | 2025-11-27 | — | — | US | claimed |
| EP-4583872-A1 | MGLUR5 RECEPTOR ANTAGONISTS FOR USE IN PREVENTION AND/OR TREATMENT OF BONE MARROW LESIONS (BML) AND/OR OSTEOPOROSIS, CARTILAGE LOSS, OSTEOSCLEROSIS, OSTEITIS IN A MAMMAL | ORPHELION AB (SE) | 2025-07-16 | — | — | EP | claimed |
| EP-4539843-A1 | TREATMENT OF FIBROTIC DISORDERS WITH METABOTROPIC GLUTAMATE RECEPTOR 5 ANTAGONISTS OR/AND CANNABINOID RECEPTOR 1 ANTAGONISTS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-04-23 | — | — | EP | claimed |
| CN-119677515-A | Treatment of fibrotic diseases using metabotropic glutamate receptor 5 antagonists or/and cannabinoid receptor 1 antagonists | 美国政府健康及人类服务部 | 2025-03-21 | — | — | CN | claimed |
| US-20250073216-A1 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | HOFFMANN LA ROCHE (CH) | 2025-03-06 | — | — | US | claimed |
| US-20240335430-A1 | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases | UNIV YALE (US) | 2024-10-10 | — | — | US | claimed |
| WO-2024189127-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | PROLEVI BIO AB (SE) | 2024-09-19 | — | — | WO | claimed |
| US-20080119489-A1 | IMIDAZOLE DERIVATIVES | BUETTELMANN BERND | 2008-05-22 | — | — | US | claimed |
| US-7332510-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-02-19 | — | — | US | claimed |
| EP-1636206-B1 | IMIDAZOLE DERIVATIVES AS GLUTMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-10-31 | — | — | EP | claimed |
| EP-1756086-A1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-28 | — | — | EP | claimed |
| EP-1636206-A1 | IMIDAZOLE DERIVATIVES AS GLUTMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-22 | — | — | EP | claimed |
| US-20060030559-A1 | Diazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | claimed |
| WO-2005118568-A1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-15 | — | — | WO | claimed |
| US-20050143375-A1 | Imidazole derivatives | ROCHE PALO ALTO LLC | 2005-06-30 | — | — | US | claimed |
| WO-2004108701-A1 | IMIDAZOLE DERIVATIVES AS GLUTMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-16 | — | — | WO | claimed |
| US-20040248888-A1 | Imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-12-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030559-A1 | Diazole derivatives | GRM1, GRM2, GRIN2B | GRM5 14/4885KCNH2 551/4885ADRB3 1151/4885 |
| US-20080119489-A1 | IMIDAZOLE DERIVATIVES | GRIK5, GRM5, GRIN2B | GRM5 2/4885KCNH2 140/4885ADRB3 806/4885 |
| US-20260124188-A1 | mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal | GRM5, OPRL1, GRM1 | GRM5 1/4885KCNH2 2941/4885ADRB3 489/4885 |
| US-12605367-B2 | Methods of treatment and/or prevention of disorders and symptoms related to BKCa and/or SK channelophathies | KCNN3, KCNN1, KCNN2 | GRM5 672/4885KCNH2 110/4885ADRB3 748/4885 |
| US-20250073216-A1 | Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists | GRM5, GRIK5, GRM1 | GRM5 1/4885KCNH2 1554/4885ADRB3 2864/4885 |
| US-20040248888-A1 | Imidazole derivatives | GRIK5, GRM5, GRIN2B | GRM5 2/4885KCNH2 115/4885ADRB3 991/4885 |
| US-20050143375-A1 | Imidazole derivatives | GRM5, GRIK5, GRM2 | GRM5 1/4885KCNH2 1004/4885ADRB3 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.